Phase I trial of ribociclib with platinum chemotherapy in ovarian cancer

BACKGROUND: New therapeutic combinations to improve outcomes of patients with ovarian cancer are clearly needed. Preclinical studies with ribociclib (LEE-011), a CDK4/6 cell cycle checkpoint inhibitor, demonstrate a synergistic effect with platinum chemotherapy and efficacy as a maintenance therapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Coffman, Lan G., Orellana, Taylor J., Liu, Tianshi, Frisbie, Leonard G., Normolle, Daniel, Griffith, Kent, Uppal, Shitanshu, McLean, Karen, Berger, Jessica, Boisen, Michelle, Courtney-Brooks, Madeleine, Edwards, Robert P., Lesnock, Jamie, Mahdi, Haider, Olawaiye, Alexander, Sukumvanich, Paniti, Taylor, Sarah E., Buckanovich, Ronald
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2022
Materias:
Clinical Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9675476/
https://www.ncbi.nlm.nih.gov/pubmed/35972817
http://dx.doi.org/10.1172/jci.insight.160573

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9675476/
https://www.ncbi.nlm.nih.gov/pubmed/35972817
http://dx.doi.org/10.1172/jci.insight.160573

Ejemplares similares